cetpinhibition.org

Genetics

CETP TaqIB polymorphism flags high coronary risk but cannot distinguish left main from more peripheral disease (Lipids Health Dis 2011)

Original title: The role of common variants of the cholesteryl ester transfer protein gene in left main coronary artery disease

Lipids Health Dis · · 5

Kolovou G, Vasiliadis I, Kolovou V, Karakosta A, Mavrogeni S, Papadopoulou E, Papamentzelopoulos S, Giannakopoulou V, Marvaki A, Degiannis D, Bilianou H

This study analyzed the CETP TaqIB and I405V polymorphisms in 471 subjects: 133 with angiographically documented left main coronary artery disease (LMCAD), 241 with more peripheral coronary artery disease (MPCAD), and 97 self-reported healthy controls. There was no significant difference in CETP allele frequency or genotype distribution between LMCAD and MPCAD patients, but there was a significant difference between LMCAD and controls (p=0.001): the B1B1 genotype was more frequent in LMCAD (33.8% vs 22.9%), the B2B2 genotype was three times less frequent in LMCAD (10.5% vs 30.2%), and the B1 allele was more frequent in LMCAD (62% vs 46%, p=0.001). This relationship was independent of lipid profile, except for apolipoprotein A. The authors conclude TaqIB polymorphism may be useful for screening high coronary risk individuals, but cannot distinguish LMCAD from MPCAD.

Read the paper (DOI)PubMed

Original abstract

Background: The cholesteryl ester transfer protein (CETP) has a central role in the lipid metabolism and therefore may alter the susceptibility to atherosclerosis.

Methods: The DNA of 471 subjects [133 subjects with angiographically documented left main coronary artery disease (LMCAD), 241 subjects with more peripheral coronary artery disease (MPCAD) and 97 subjects self reported healthy (Controls)] was analyzed for the frequency of TaqIB and I405V polymorphisms in the gene coding CETP.

Results: There is no significant difference in CETP allele frequency or genotype distribution among LMCAD and MPCAD patients although there is statistical difference between LMCAD and Controls (p = 0.001). Specifically, patients with LMCAD and B1B1 genotype of TaqIB polymorphism were more frequent present compared to Controls (33.8% vs 22.9%, respectively). The frequency of B2B2 genotype was 3 times lower in the LMCAD group compared to Controls (10.5% vs 30.2%, respectively). In the LMCAD group the frequency of B1 allele compared to Controls was higher (62% vs 46%, respectively, p = 0.001). The relationship between TaqIB gene polymorphism and the LMCAD was independent of lipid profile, with the exception of apolipoprotein A.

Conclusions: These findings indicate that the TaqIB polymorphism may have potential importance in screening individuals at high risk for developing CAD. However, this polymorphism cannot distinguish between LMCAD and MPCAD. Further prospective investigations in larger populations are required to confirm these findings.

genetics

Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.